Embedded Files
Vision
Vision
To be recognized as a national research center for medical and health technology assessment in Thailand
Missions
Missions
To produce high-quality research works in the field of medical, pharmaceutical, and health technology assessment including economic evaluation, secondary data analysis, and evidence synthesis
To provide research consultation for government and private sectors
To provide academic services in the related fields
About the Center
The Center for Medical and Health Technology Assessment (CM-HTA) was established in 2022 as a research center under the Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University. The primary objective of the center is to produce high-quality research works in the field of health technology assessment (HTA). The scope of research of the center is primarily economic evaluation. However, secondary data analysis and evidence synthesis are also within the scope of the center. Additionally, the center is responsible for providing research consultation and academic services in related fields for both government and private sectors.
Members
Director of the center
Director of the center
Associate Professor Dr. Piyameth Dilokthornsakul PharmD., PhD.
Dr. Dilokthornsakul is an HTA researcher. His expertise is in health economic modeling, secondary data analysis, systematic review, and network meta-analysis. His research focuses on the fields of chronic diseases, especially respiratory, cardiology, and immunology. In addition, he is also interested in the economic evaluation of vaccines.
Contact: piyameth.dilok@cmu.ac.th
Deputy director of the center
Deputy director of the center
Associate Professor Dr. Unchalee Permsuwan BPharm., PhD.
Dr. Permsuwan is a HTA researcher. Her work focuses on the economic evaluation of health interventions, including pharmaceuticals and diagnostic tests. Her clinical research focus is in the field of cardiology.
Contact: unchalee.permsuwan@cmu.ac.th
Secretary/member
Secretary/member
Assistant Professor Dr. Witoo Dilokthornsakul BPharm., PhD.
Dr. Dilokthornsakul is a pharmacologist who is interested in applying her knowledge to pharmacoeconomics and outcomes research. Her work mostly focuses on a systematic review and meta-analysis of the treatment effect, safety, and toxicity of medications from both laboratory and clinical aspects. Her clinical research focus is in the fields of endocrinology and toxicology.
Contact: witoo.dilok@cmu.ac.th
Member
Member
Dr. Jirawit Tadee PharmD.
Dr. Yadee is an HTA researcher. His expertise is in the economic evaluation of chronic diseases. His clinical research focus is in the field of cardiology.
Contact: jirawit.n@gmail.com
Member
Member
Assistant Professor Dr. Mantiwee Nimworapan PharmD., BCPS
Dr. Mantiwee is a cardiology pharmacist and an instructor in clinical pharmacy. She is also interested in real-world outcome research, systematic review, and meta-analysis. Her research focuses on the real-world outcomes and evidence synthesis of medications used in cardiology and thrombosis.
Contact: manthiwee.nim@cmu.ac.th
Member
Member
Dr. Suthinee Taesotikul Pharm.D. (Pharmaceutical care), BCP
Dr. Taesotikul is a clinical pharmacist specializing in critical care and an instructor in clinical pharmacy. She is also interested in real-world outcome research to improve patient safety and optimize medical effectiveness, especially in critically ill patients with medical and surgical conditions. Her research focuses on antibiotics, sedatives, opioids, and supportive medications in the ICU.
Contact: suthinee.tae@cmu.ac.th
Member
Member
Assistant Professor Dr. Buntitabhon Sirichanchuen BPharm., PhD.
Dr. Sirichanchuen is a lecturer in topics involving pharmacotherapy in gastrointestinal diseases and oncology. She also serves as a clinical pharmacist in the warfarin clinic and oncology unit. Her clinical research mostly focuses on the efficacy and safety of medicines used in cancer treatment. She is also interested in a systematic review and meta-analysis of drugs or dietary supplements for cancer.
Contact: buntitabhon.s@cmu.ac.th
Publication
1. Yadee J, Slisatkorn W, Singhatanadgige S, et al. Trends in Economic Burden and Mortality of Hospitalized Patients With Aortic Stenosis in Thailand. Am J Cardiol 2023;205:269-75. doi: 10.1016/j.amjcard.2023.07.131 [published Online First: 20230822]
2. Krittayaphong R, Permsuwan U. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction. Am J Cardiovasc Drugs 2022;22(5):577-90. doi: 10.1007/s40256-022-00542-9 [published Online First: 20220707]
3. Krittayaphong R, Permsuwan U. Employing Real-World Evidence for the Economic Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation in Thailand. Appl Health Econ Health Policy 2024;22(5):725-34. doi: 10.1007/s40258-024-00891-3 [published Online First: 20240610]
4. Permsuwan U, Yoodee V, Buddhari W, et al. Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand. Clinicoecon Outcomes Res 2022;14:487-98. doi: 10.2147/ceor.S371417 [published Online First: 20220723]
5. Dilokthornsakul P, Rattanachaisit N, Thimkorn P, et al. Clinical effects of Hibiscus sabdariffa Linn. on obesity treatment: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2024;84:103063. doi: 10.1016/j.ctim.2024.103063 [published Online First: 20240613]
6. Kosachunhanun N, Wongsa D, Permsuwan U. Factors and economic burden of non-severe hypoglycemia among insulin-treated type 2 diabetes patients: a cross-sectional study. Curr Med Res Opin 2024;40(3):385-93. doi: 10.1080/03007995.2024.2312160 [published Online First: 20240212]
7. Deerochanawong C, Krittayaphong R, Romano JGU, et al. Correction to: Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes Ther 2023;14(5):947-49. doi: 10.1007/s13300-023-01392-7
8. Deerochanawong C, Krittayaphong R, Romano JGU, et al. Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes Ther 2023;14(3):531-52. doi: 10.1007/s13300-023-01371-y [published Online First: 20230131]
9. Petch-In P, Saokaew S, Phisalprapa P, et al. The Association of Pre-operative Serum Albumin Levels and Post-operative In-Hospital Death in Patients Undergoing Gastrointestinal Surgeries in Thailand: A Retrospective Cohort Study. Drugs Real World Outcomes 2023;10(2):341-49. doi: 10.1007/s40801-023-00364-4 [published Online First: 20230327]
10. Dilokthornsakul P, Lan LM, Thakkinstian A, et al. Economic evaluation of seasonal influenza vaccination in elderly and health workers: A systematic review and meta-analysis. EClinicalMedicine 2022;47:101410. doi: 10.1016/j.eclinm.2022.101410 [published Online First: 20220421]
11. Dilokthornsakul P, Veettil SK, Lan LM, et al. Combining cost-effectiveness results into a single measurement: What is the value?: Authors response. EClinicalMedicine 2022;51:101565. doi: 10.1016/j.eclinm.2022.101565 [published Online First: 20220715]
12. Chotnoppharatphatthara P, Yoodee V, Taesotikul S, et al. Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis. Eur J Health Econ 2023;24(3):359-76. doi: 10.1007/s10198-022-01477-3 [published Online First: 20220616]
13. Phrommintikul A, Dilokthornsakul P, Permsuwan U. Economic Burdens for Treatment of Patients With Type 2 Diabetes in North Thailand: A Hospital-Based Observational Study. Front Endocrinol (Lausanne) 2022;13:824545. doi: 10.3389/fendo.2022.824545 [published Online First: 20220516]
14. Lee LH, Goh BH, Dilokthornsakul P, et al. Editorial: Evidence-based on health benefits: probiotics, micronutrients, and edible plants. Front Nutr 2023;10:1272456. doi: 10.3389/fnut.2023.1272456 [published Online First: 20231002]
15. Chaisai C, Thavorn K, Wattanasirichaigoon S, et al. The impact of Thai multidisciplinary smoking cessation program on clinical outcomes: A multicentre prospective observational study. Front Public Health 2022;10:965020. doi: 10.3389/fpubh.2022.965020 [published Online First: 20220824]
16. Kosachunhanun N, Wongsa D, Permsuwan U. Economic Burdens of Type 2 Diabetes Hospital Visits with Hypoglycemic Episodes in the Tertiary Care Setting in Thailand. Healthcare (Basel) 2023;11(7) doi: 10.3390/healthcare11070949 [published Online First: 20230324]
17. Tangviriyapaiboon D, Permsuwan U, Pavasuthipaisit C, et al. Economic Evaluation of the Thai Diagnostic Autism Scale for Autism Spectrum Disorder Diagnosis in Children Aged 1-5 Years Old. Healthcare (Basel) 2024;12(7) doi: 10.3390/healthcare12070782 [published Online First: 20240403]
18. Lertsinudom S, Tiamkao S, Mungmanitmongkol S, et al. Telepharmacy services to support patients with epilepsy in Thailand: A descriptive study. Heliyon 2023;9(2):e13361. doi: 10.1016/j.heliyon.2023.e13361 [published Online First: 20230201]
19. Prayoonhong W, Sonsingh W, Permsuwan U. Clinical outcomes and economic evaluation of patient-centered care system versus routine-service system for patients with type 2 diabetes in Thailand. Heliyon 2024;10(3):e25093. doi: 10.1016/j.heliyon.2024.e25093 [published Online First: 20240123]
20. Niyomsri S, Nimworapan M, Wongcharoen W, et al. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis. Int J Environ Res Public Health 2023;20(4) doi: 10.3390/ijerph20043176 [published Online First: 20230211]
21. Phusahat P, Dilokthornsakul P, Boonsawat W, et al. Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial. Int J Environ Res Public Health 2022;19(20) doi: 10.3390/ijerph192013358 [published Online First: 20221016]
22. Sitanggang RJ, Chavarina KK, K CS, et al. Impact of COVID-19 pandemic on HTAsiaLink network members. Int J Technol Assess Health Care 2024;40(1):e63. doi: 10.1017/s0266462324000357 [published Online First: 20241126]
23. Pan-On S, Dilokthornsakul P, Tiyaboonchai W. Trends in advanced oral drug delivery system for curcumin: A systematic review. J Control Release 2022;348:335-45. doi: 10.1016/j.jconrel.2022.05.048 [published Online First: 20220609]
24. Permsuwan U, Yoodee V, Buddhari W, et al. Cost-utility analysis of transcatheter aortic valve implantation versus surgery in severe aortic stenosis patients with intermediate surgical risk in Thailand. J Geriatr Cardiol 2022;19(11):822-32. doi: 10.11909/j.issn.1671-5411.2022.11.007
25. Taburee W, Dhippayom T, Nagaviroj K, et al. Effects of Anticholinergics on Death Rattle: A Systematic Review and Network Meta-Analysis. J Palliat Med 2023;26(3):431-40. doi: 10.1089/jpm.2022.0386 [published Online First: 20221003]
26. Trerayapiwat K, Jinatongthai P, Vathesatogkit P, et al. Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand. Lancet Reg Health West Pac 2022;26:100503. doi: 10.1016/j.lanwpc.2022.100503 [published Online First: 20220624]
27. Tipduangta P, Chansakaow S, Tansakul P, et al. Polymer Matrix and Manufacturing Methods in Solid Dispersion System for Enhancing Andrographolide Solubility and Absorption: A Systematic Review. Pharmaceutics 2024;16(5) doi: 10.3390/pharmaceutics16050688 [published Online First: 20240520]
28. Dilokthornsakul P, Sawangjit R, Noppakun N, et al. Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation. PLoS One 2024;19(8):e0307050. doi: 10.1371/journal.pone.0307050 [published Online First: 20240809]
29. Permsuwan U, Singhatanadgige S, Boonpipattanapong K, et al. Cost-utility analysis of sutureless and rapid deployment versus conventional aortic valve replacement in patients with moderate to severe aortic stenosis in Thailand. PLoS One 2024;19(1):e0296875. doi: 10.1371/journal.pone.0296875 [published Online First: 20240119]
30. Chai-Adisaksopha C, Watanabe AH, Dilokthornsakul P, et al. Impact of type of anticoagulant on clinical outcomes in cancer patients who had atrial fibrillation. Sci Rep 2023;13(1):10937. doi: 10.1038/s41598-023-38071-3 [published Online First: 20230706]
31. Yadee J, Permsuwan U, Guntawongwan K, et al. Discounting money and health effects from communicable and noncommunicable diseases in Thailand. Sci Rep 2023;13(1):3324. doi: 10.1038/s41598-023-30559-2 [published Online First: 20230227]
32. Chaiyakunapruk N, Song D, Lynch J, et al. Public Health Value of a Hypothetical Pneumococcal Conjugate Vaccine (PCV) Introduction: A Case Study. Vaccines (Basel) 2022;10(6) doi: 10.3390/vaccines10060950 [published Online First: 20220615]
33. Dilokthornsakul P, Sawangjit R, Osiri M, et al. Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand. Value Health Reg Issues 2023;34:40-47. doi: 10.1016/j.vhri.2022.10.005 [published Online First: 20221202]
34. Dilokthornsakul P, Sawangjit R, Tangkijvanich P, et al. Simplified Chronic Hepatitis B Antiviral Initiation Criteria in Thailand: An Economic Evaluation. Value Health Reg Issues 2024;43:101011. doi: 10.1016/j.vhri.2024.101011 [published Online First: 20240607]
Better decision better health
Better decision better health
Facebook page: The Center for Medical and Health Technology Assessment
Page updated
Google Sites
Report abuse